## T lymphocyte trafficking: molecules and mechanisms

#### Hongmei Fu<sup>1</sup>, Amu Wang<sup>2</sup>, Claudio Mauro<sup>1</sup>, Federica Marelli-Berg<sup>1,2</sup>

<sup>1</sup>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK, <sup>2</sup>Section of Immunobiology, Department of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK

# TABLE OF CONTENTS

1. Abstract

- 2. Introduction Lymphocyte recirculation and homing
- 3. T lymphocyte extravasation
- 4. Naïve T cell homing to the peripheral lymph nodes (PLN) and gut-associated lymphoid tissue
- 5. Memory T cell homing to non-lymphoid tissue
  - 5.1. Memory T cell homing to the skin
  - 5.2. Memory T cell homing to the small and large intestine
  - 5.3. Memory T cell homing to the liver
  - 5.4. Mechanisms of homing receptor acquisition
  - 5.5. Antigen-driven T cell trafficking
  - 5.6. Co-stimulatory molecules regulate T cell migration
  - 5.7. PI3K—mediated control of T cell migration
- 6. Regulatory T cell trafficking
  - 6.1. Naturally occurring regulatory T cells
  - 6.2. Induced regulatory T cells
  - 6.3. T<sub>regs</sub> homing to secondary lymphoid organs
  - 6.4. T<sub>regs</sub> homing to nonlymphoid tissue
- 7. Concluding remarks
- 8. Acknowledgements

9. References

#### 1. ABSTRACT

Coordinated migratory events are required for the development of effective and regulated immunity. Naïve T lymphocytes are programmed to recirculate predominantly in secondary lymphoid tissue by non-specific stimuli. In contrast, primed T cells must identify specific sites of antigen location in non-lymphoid tissue to exert targeted effector responses. Following priming, T cells acquire the ability to establish molecular interactions mediated by tissue-selective adhesion and chemokine receptors (homing receptors) that facilitate their access to specific organs. Recent studies have shown that an additional level of homing specificity is provided by the induction of T cell migration into the tissue by recognition of antigen displayed by the endothelium. In addition, co-stimulatory signals have been recently shown not only to regulate T cell activation and differentiation, but also to orchestrate the anatomy of the ensuing T cell response. Similarly, the characterization of migratory patterns by regulatory T cells has been the subject of many recent studies. Here, we provide an overview of key concepts, which have contribute to unraveling the complex anatomy of T cell immunity.

## 2. INTRODUCTION - LYMPHOCYTE RECIRCULATION AND HOMING

Effective immune responses are dependent on the continuous trafficking of lymphocytes through blood, lymphoid organs and non-lymphoid tissue in a process known as recirculation (1). While other leukocytes migrate in response to non-specific inflammatory stimuli, the migratory patterns of naïve and memory T lymphocytes are well defined and vary depending on their activation, differentiation and function (2). For instance, naive T cells express L-selectin (CD62L) and chemokine receptor CCR7 and predominantly traffic to secondary lymphoid organs (SLOs) whereas antigen-experienced T cells acquire the ability to migrate to non-lymphoid sites of inflammation in the tissues where antigens are located (3, 4). By possessing a unique set of adhesion molecules and chemokine receptors - the 'homing' receptors, distinct memory T cell populations are able to interact with organ-specific endothelial cells (EC) and are recruited to distinct target tissues (5, 6). For example, lymphocyte trafficking to the intestinal lamina propria is mediated predominantly by the interaction between intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and lymphocyte  $\alpha_4\beta_7$ 

integrin (7). Human T cell homing to the skin requires the binding of cutaneous lymphocyte antigens (CLA, an E–selectin ligand) and the chemokine receptor CCR4 to the vascular lectin endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) and the thymus and activation-regulated chemokine (TARC, CCL17) respectively (8, 9).

## **3. T LYMPHOCYTE EXTRAVASATION**

The physiological process by which lymphocytes leave circulation, find and localize to particular tissues and to the microenvironment therein is known as extravasation (10). A wide range of chemokines, adhesion molecules and junctional molecules expressed on the EC are required to mediate and regulate this tightly controlled process. These molecules bind to their counter receptors on the migrating lymphocytes directing their entry into the tissue. Monocytes and neutrophil migration also involves a cascade-like process similar to lymphocytes (11).

In healthy tissue, the vascular endothelium is impermeable to macromolecules; it forms a nonthrombotic, non-adhesive barrier (12). Upon inflammation, the endothelial monolayer undergoes physiological and molecular changes such as the up-regulation of adhesion molecule expression. This in turn allows the exit of lymphocytes across the endothelium into the tissue without disrupting the endothelium integrity. The initial stage of lymphocyte trafficking is mostly mediated by selectins, which belong to a group of so-called C-type lectins expressed exclusively on bone marrow derived cells and ECs (13). Selectins are responsible for the initial contact between the circulating lymphocytes and the endothelium monolayer, and mediate lymphocyte tethering and rolling on the endothelium.

After this initial contact, locally produced chemokines displayed on the ECs bind to their receptors and subsequently induce integrin activation (14). Chemokine signalling induces integrin conformational changes leading to the upregulation of integrin affinity; alternatively it triggers integrin clustering on the cell surface thus increasing integrin avidity (14, 15). Activated integrins bind to their ligands on the EC leading to the establishment of firm adhesion of migrating leukocytes to the endothelial cells. This step of extravasation is thus referred to as activation (16).

Chemokines are small proteins of 8-14 kDa with chemotactic properties, which control cell trafficking. Chemokines can be categorized based on their functions; those that are homeostatic and produced constitutively and those that are induced during inflammation (17). Homeostatic chemokines are important during hematopoiesis in the bone marrow and thymus. They also control cellular traffic in the SLOs and contribute to the immune surveillance of the peripheral tissues. Inflammatory chemokines on the other hand recruit effector leukocytes as well as cells of the innate immune system to the sites of inflammation (17, 18). Chemokines may be synthesized by the endothelium itself and released on the luminal surface where they are immobilized on glycosaminoglycans (GAGs) synthesized by the vascular endothelium for binding to their receptors on the incoming lymphocytes; alternatively, they are produced by tissue parenchymal cells and transported across the endothelium (19).

Following the activation step, lymphocytes firmly adhere to and spread on the endothelial surface in a process called firm adhesion or 'arrest'. Integrins comprise a major group of adhesion molecules and consist of two noncovalently bound polypeptide chains -  $\alpha$  and  $\beta$  chains. Integrins are categorized based on the type of  $\beta$  chain. For example,  $\beta_1$  integrins include VLA1 ( $\alpha_1\beta_1$ ), and VLA4 ( $\alpha_4\beta_1$ );  $\beta$ 2 integrins include the leukocyte associated function antigen 1 (LFA-1),  $\alpha_1\beta_2$ , and the integrin  $\alpha_4\beta_7$  which is important in T cell homing to the gut (20). During the activation step of lymphocyte extravasation, integrins bind to their ligands expressed on the endothelium such as the ICAMs, VCAM-1, and MAdCAM-1, which lead to the firm arrest of lymphocytes on the endothelium. Following firm adhesion on the EC monolayer, lymphocytes eventually transmigrate into the target tissue. Lymphocyte transendothelial migration occurs at the junction between apposing endothelial cells (paracellular route) without disrupting the EC monolayer in a complex process known as diapedesis involving the junctional adhesion molecules (21). Alternatively, leukocytes can migrate across the endothelial cell body into the tissue known as the transcellular route (22). This phenomenon was first observed in a mouse model of experimental autoimmune encephalomyelitis (23) and shown to be ICAM-1 dependent (24). It has been proposed that the contribution of either of such transmigration pathway depends on the type of blood vessel, target tissue, recruitment stimuli (25). Once across the endothelial barrier, migrating lymphocytes continue to move through the subendothelial matrix (21) and the extravascular tissue to the site of inflammation in response to chemotactic gradients (12).

Naïve and memory T cells display different surface phenotypes, which define their functional properties and migratory patterns (26-29). Naïve T cells have little or no ability to produce cytokines (30). They recirculate from the blood, through SLOs, into the lymphatic vessels and back to the blood in search of their cognate antigen (5, 31). SLOs include peripheral lymph nodes, gut-associated lymphoid tissue (GALT, including Peyer's patches (PP), bronchus-associated lymphoid tissue (BALT), and the spleen (32). In the SLOs, naïve T lymphocytes are activated upon recognition of antigen presented by tissue-resident dendritic cells (priming), and undergo clonal expansion and differentiation into effector and memory T cells. Naive T cells enter the lymph nodes via high endothelial venules (HEVs), which are specialized postcapillary venules characterized by plump, cuboidal shapes and exclusively found in the SLOs (33, 34).

A recent study suggested that DCs sustain the entry of naive lymphocytes to lymph nodes by modulating the phenotype of HEVs during homeostasis in adult mice. HEV-mediated lymphocyte recruitment to lymph nodes is inhibited in the absence of DCs. The effect of DCs on HEV is direct and requires lymphotoxin- $\beta$ -receptor-dependent signalling (35).

Homing of naïve T cells to the peripheral lymph nodes (PLN) requires the expression of L-selectin (CD62L) and the chemokine receptor CCR7 (Table 1). L-selectin binds to peripheral lymph node addressin (PNad), which is highly expressed on the HEVs of PLNs and mesenteric lymph nodes (MLNs) (36), while CCR7 binds to the chemokines CCL19 and CCL21 expressed by HEVs of the PLNs (37, 38). CCL21 is also expressed in PPs (39). Naïve T cells have also been shown to utilize CXCR4, which is the receptor for stromal cell-derived factor1 (SDF-1, CXCL12) chemokine to circulate through secondary lymphoid tissues (40).

In humans, the majority of T cells entering the PPs are found to be naïve T cells. This process requires the interaction of integrin  $\alpha_4\beta_7$  on T cells and MAdCAM-1 on the mucosal vasculature (7, 39). Consistent with this observation, human naïve T cells are found to constitutively express low levels of  $\alpha_4\beta_7$  (41, 42). Studies subsequently showed that both CD62-L and integrin  $\alpha_4\beta_7$ are required in a sequential and synergistic manner to mediate naïve T cell migration to the mesenteric lymph nodes (43). CD62-L binds to the PNad expressed on the MLNs, which induces the initial rolling and tethering of T cells during transendothelial migration;  $\alpha_4\beta_7$  integrins subsequently bind to MAdCAM-1 and mediate firm adhesion and transmigration (43). Mice lacking  $\beta_7$  integrin expression have been found to display a 90% reduction in lymphocyte migration to the PPs; and T cell migration is reduced by 55% in mice that are deficient for CD62-L (43). Collectively, this evidence highlights the importance of both CD62-L and integrin  $\alpha_4\beta_7$  in naïve T cell homing to the gut secondary lymphoid tissue.

# 5. MEMORY T CELL HOMING TO NON-LYMPHOID TISSUE

Upon encountering antigens in SLOs, naïve T cells are sequestered and interact with antigens for 2-3 days (44). Naïve T cells subsequently differentiate into short-lived effector T cells or long-lived memory T cell populations. Memory T cells leave the SLOs via the efferent lymphatics, enter the blood circulation through the thoracic duct and travel to the inflamed tissue (Figure 1). As previously mentioned, memory T cells are a heterogeneous population consisting of long-lived central memory T cells ( $T_{CM}$ ), short-lived effector T cells ( $T_{EFF}$ ) and long-lived effector memory T cells ( $T_{EM}$ ); these cells are defined by their different phenotypes, functions and migratory patterns (45, 46).

Similar to naïve T cells,  $T_{CM}$  express CD62-L and CCR7, and share migratory patterns with naive T cells; however, unlike naïve T cells they also express inflammatory chemokine receptors which enable them to enter sites of chronic inflammation (11).  $T_{CM}$  do not have immediate effector functions but are able to proliferate rapidly during secondary immune responses (47). In contrast, both short-lived  $T_{EFF}$  and long-lived  $T_{EM}$  lack the expression of CD62L and CCR7. They use instead tissue-specific integrins and chemokine receptors to preferentially migrate to non-lymphoid tissues (46, 48). Short-lived TEFF represent mostly recently activated T cells, and are eliminated at the end of primary immune responses (29, 49). TEM have immediate effector function, and are present in the blood, peripheral tissues, spleen but not in the resting lymph nodes (50). A recent study revealed that murine TEM and TEFF can also be recruited to the reactive lymph nodes in a CCR7 independent pathway via the chemokine receptor CXCR3 in order to kill antigen-presenting dendritic cells thus preventing excessive T cell stimulation (51).


Unlike naïve T cells predominantly trafficking to the SLOs, memory T cells are endowed with the ability of infiltrating non-lymphoid tissue. Upregulation of the integrins LFA-1 and VLA-4 facilitate this process. In addition, tissue-selective molecular interactions (homing receptor/ligand pairs) target these cells to the tissues where pathogen invasion has first occurred.

The mechanisms used by memory T cells to leave parenchymal tissue and return to the circulation have been only partially characterized. The chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics (52). Promotion of lymphocyte egress into blood and lymph is sustained by distinct sources of sphingosine-1-phosphate (53). After exit from the tissue, memory T cells may continue recirculating in the blood or localize in 'reservoir' niches: memory T cells tend to preferentially reside in the spleen in chronic inflammation with antigen persistence; alternatively they localize to the bone marrow if the infectious/inflammatory process is acute but transient (46, 54, 55) (Figure 1).

Although the molecular interactions guiding T cell homing to the gut and skin are relatively well defined, mapping of T cell homing to other solid organs has revealed a great level of overlap and - perhaps with the exception of the liver (56) – other organ-specific homing receptor/ligand pairs have not yet been identified. In addition, given the size of skin and gut, further mechanism are likely to be in place which allow T cells to discriminate not only the area code for these tissues, but also the specific 'address' of antigen location.

# 5.1. Memory T cell homing to the skin

Human memory  $\overline{T}$  cells require the expression of CLA to traffic to the skin by binding to E-selectin (CD62E, ELAM-1, endothelial cell-leukocyte adhesion molecule) which is constitutively expressed at a low level by endothelial cells in the skin and is upregulated upon cutaneous inflammation (9, 57). Human skin-infiltrating lymphocytes also express CCR4, the chemokine receptor for CCL17 (also known as the thymus and activation-regulated chemokine, TARC) displayed on the skin venules (8). Effector/memory T cell trafficking to skin depends on E-selectin, P-selectin and CCR4 (58). Further studies



**Figure 1.** T-cell migration into lymphoid and non-lymphoid tissues. Naïve T cells priming and homing molecules acquisition. Naïve T cells migrate from the circulation (HEV) into lymph nodes by utilizing the lymphoid tissue homing receptors L-selectin and CCR7. DCs present antigens to naïve T cells, which subsequently differentiate into  $T_{EFF}$ ,  $T_{EM}$  and  $T_{CM}$ . During priming, different homing receptors are acquired depending on the local microenvironment. T cells activated in the cutaneous secondary lymphoid tissue express skin-homing receptors CCR10 due to presence of 1,25 (OH) (2)D (3), the active form of vitamin D3. T cells activated in the mesenteric lymph nodes expressed gut-homing receptors CCR9 and  $\alpha4\beta7$  due to RA production from vitamin A by resident DCs. Primed T cells migrate to their target tissues. T-cell receptor (TCR) engagement by endothelium and tissue resident antigen presenting cells (APC) is instrumental to the selectivity of antigen-specific T cell recruitment and retention. Chemokine receptor engagement also facilitates the recruitment of specific T cells into the tissue. After exit from tissue, memory T cells may continue recirculating in the blood, or display prolonged localization into niches: memory T cells home preferentially to spleen if antigen persists after infection; alternatively, they localize to the bone marrow if the inflammation is acute but transient.

revealed that CCL27 (the cutaneous T cell-attracting chemokine, CTACK) is also crucial for attracting CLA<sup>+</sup> memory T cells to the skin by binding to its receptor CCR10 (59). CCR10 is important for the development of skin-specific T cells by regulating their migration and location (60). Other key molecules participating in memory T cell homing to skin include intergrin  $\alpha_4\beta_1$  (VLA-1), which binds to vascular cell adhesion molecule 1 (VCAM-1) expressed by the endothelium in non-mucosal site of inflammation (42). T cells expressing high levels of  $\alpha_4\beta_1$  preferentially home to the systemic non-mucosal sites including the skin, central nervous system and bone marrow (61). (Table 1).

# 5.2. Memory T cell homing to the small and large intestine

Effector and memory T cells and B cells require the interaction of integrin  $\alpha_4\beta_7$  and MAdCAM-1 to migrate to the effector site of the gut mucosa – the *lamina propria*  (7, 62). Human peripheral blood CD4<sup>+</sup>, CD8<sup>+</sup> T cells and B cells have heterogeneous expression of  $\alpha_4\beta_7$  (41, 63). The level of  $\alpha_4\beta_7$  expression is much higher on memory cells than naïve cells (41, 42). The ability of  $\alpha_4\beta_7$  expressing cells to bind to MAdCAM-1 is influenced by the level of  $\alpha_4\beta_7$  expression and its functional state (41). MAdCAM-1 is constitutively expressed on the postcapillary venules of intestinal *lamina propria*, the MLNs, the HEVs of the PPs (3) and the endothelial venules of both small intestine and colon (64). Other than its crucial function in mediating lymphocyte homing to the gut, studies in mice have also revealed that  $\alpha_4\beta_7$  plays a critical role in the formation of gut-associate lymphoid tissue (65). Mice lacking MAdCAM-1 have a disordered architecture in their PPs and MLNs (66).

Upon arrival in the small intestine *lamina propria*, some T cells further migrate to the gut epithelium to become intraepithelial T cells in a process dependent on

Lymphocyte homing receptor	Receptor induction	Ligand	Homing tissue	Reference
CCR7		CCL19, CCL21	SLOs	(37, 38)
L-selectin		PNad	SLOs	(36)
CCR9	RA	CCL25	Intestine	(69-72)
α4β7	RA	MAdCAM-1	Intestine	(3, 41, 64)
CLA		E-selectin	Skin	(9, 57)
CCR4		CCL17	Skin	(8, 58)
CCR10		CCL27	Skin	(59)
? (Th2)		VAP-1	Liver	(79)
CD44		hyaluronate	Liver	(80)

**Table 1.** Lymphocyte receptors associated to tissue-selective homing

Abbreviations: CLA, cutaneous lymphocyte antigens

the interaction of chemokine receptor CCR9 and its ligand CCL25 (also known as the thymus expressed chemokine TECK in humans and mice) (67-69) (Table 1). CCL25 is expressed in the thymus and the small intestinal glands and crypts (70). CCL25 is also expressed by gut endothelium and epithelial cells in mice (71). Within the murine small intestine, CCL25 is found at a higher concentration at the proximal segments compared to the distal segments (71). Its receptor CCR9 is expressed by thymic T cells,  $\alpha_4\beta_7^+$  *lamina propria* T cells and intraepithelial lymphocytes in the small intestine as well as IgA- secreting plasma cells in the secondary lymphoid organs in humans and mice (68, 69, 72).

In mice, the CCR9-CCL25 axis has been shown to play a key role in the homing of antigen-specific CD8<sup>+</sup> T lymphocytes to the small intestine *lamina propria* (73), but less so for CD4<sup>+</sup> effector T cells (74). Other studies have also described that CCL25 plays a key role in the generation of murine small intestinal intraepithelial lymphocytes (75). In humans, CCL25 is abundantly expressed in various regions of the small intestine (jejunum and the ileum), but not in the colon or the caecum (68, 76). Consistently, CCR9 is found on all of the small intestinal *lamina propria* intraepithelial CD4<sup>+</sup> and CD8<sup>+</sup> T cells (68, 76).

In line with these observations, CCR9-CCL25 interactions are required for memory T cell homing to the small intestine, while they do not appear to be essential for T cell migration to the colon in humans or mice (68, 77). Blockade of CCL25 had no effect on murine T cell adhesion in the colon in both non-inflamed and inflamed conditions, while it significantly inhibited T cell adhesion in the small intestine (78). In humans, there is no evidence suggesting that CCL25-CCR9 interaction is required for lymphocyte homing to the healthy or inflamed colon (70). Over 90% of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells isolated from the human small intestine (including intraepithelial CD8<sup>+</sup> T cells) express CCR9, in contrast only 25% of colonic CD4<sup>+</sup> and CD8<sup>+</sup>T cells are CCR9 positive (68, 76). In human peripheral blood, only a small percentage of total circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells co-express  $\alpha_4\beta_7^+$  and CCR9, further enforcing the concept that T cell homing to the small and large intestine may not be achieved via the same pathways (69). Instead, CCL25 may be responsible for compartmentalizing the mucosal immune responses within the gut (68, 72).

The expression of homing receptors on T cells for the skin and the gut are mutually exclusive (42). For instance, CCR4 is exclusively expressed by CLA<sup>+</sup> skinhoming T cells but not by intestinal memory T cells (8), and the integrin  $\alpha_4\beta_1$  targets T cells to the non-mucosal sites whereas integrin  $\alpha_4\beta_7$  targets memory T cells to the intestine (42).

## 5.3. Memory T cell homing to the liver

Besides the skin and the gut, T cell homing to the liver has received much attention in recent years, and a number of molecular mediators of T cell localization to hepatic tissue have been identified (Table 1). Studies in experimental models of liver inflammation have indicated that Th1 cells may use very late antigen-4 (VLA-4) to traffic to liver, whilst Th2 cells may use a presently uncharacterized ligand for endothelial vascular adhesion protein-1 (VAP-1), which is constitutively expressed on hepatic venules and sinusoids and locally up-regulated during inflammation (79). Other reports suggested the involvement of the hyaluronan receptor CD44 in lymphocyte homing to liver (80). Several circumstantial evidences support a role of CCR5 as a mediator of recruitment of T cells in the liver during acute inflammation as well as during numerous autoimmune diseases, including multiple sclerosis, rheumatoid arthritis and type I diabetes (81). First, T cell-mediated immune responses play a critical role in hepatocyte damage induced by autoimmunity and viral infections, and CCR5 is preferentially expressed on Th1 cells (82, 83). Second, recent clinical trials of some CCR5 antagonists were abruptly halted, due to profound hepatotoxicity (81). In addition. CCR5 deficiency in humans, as well as in experimental animal models of inflammation and infection, is associated with significant increase in tissue levels of the CCR5 ligand CCL5 (84, 85). Elevated tissue levels of CCL5 could in turn promote enhanced influx of leukocytes (including T cells) by binding to its alternative receptor, CCR1, expressed on circulating leukocytes (84, 86). The patterns of T cell migration to the intestine and the skin have been well characterized.

#### 5.4. Mechanisms of homing receptor acquisition

The ability of local lymphoid tissue to imprint T lymphocytes with a specific set of homing receptors has long been recognized. It was first demonstrated in mice that only DCs isolated from the MLNs and the PPs preferentially up-regulated integrin  $\alpha 4\beta7$  and chemokine receptor CCR9 when activating naïve T cells (73, 87, 88). In contrast, T cells activated in the cutaneous secondary lymphoid tissue expressed skin-homing receptors (88, 89). The mutually exclusive sets of skin and gut-homing receptors expressed by T cells commit them to either

destination (42, 69). These results highlighted the importance of local microenvironment in T cell acquisition of homing receptors.

More recent studies have shed light on the molecular mechanisms of 'local' imprinting. Skin-resident DCs have been shown to process Vitamin D3, the inactive pro-hormone naturally generated in the skin by exposure to the sun, to 1,25 (OH) (2)D (3), the active form of vitamin D3. 1,25 (OH) (2)D (3) signals T cells to express the chemokine receptor CCR10, which enables them to migrate in response to the chemokine CCL27 secreted by keratinocytes of the epidermis. In contrast, 1,25 (OH) (2)D (3) suppresses the expression of the gut-homing receptors  $\alpha 4\beta7$  and CCR9. Hence, the ability of DCs to metabolize a local product underlies their ability to instruct T cell 'epidermotropism' (90).

Similar mechanisms have been identified which underlay the acquisition of gut homing receptors. A study by Iwata and colleagues highlighted the key role of the vitamin A metabolite retinoic acid (RA) produced by DCs in the imprinting of gut homing specificity on T cells (91). The small intestine has long been established as the primary site for the absorption and the processing of vitamin A and beta-carotenoids (92). Vitamin A enters the body exclusively through diet, and is mainly obtained as retinol from the liver, dairy products or as carotenoids from plants (93). Vitamin A is inactive and requires enzymatic processing to become activated (90). It is first converted to retinal catalyzed by alcohol dehydrogenases (ADH) commonly found in most cells, and then to RA catalyzed by retinal dehydrogenases (RALDH), which are only expressed by certain cell types including DCs found in the PPs, LPs and the MLNs in the small intestine (91, 94, 95). In the gut, vitamin A is metabolized locally by DCs resulting in the production of RA, which along with antigens is presented to naïve T cells during priming (91, 93). As a result, RA binds to its receptors - the retinoic acid receptor RAR and RXR expressed on naïve T cells, which up-regulate the expression of  $\alpha_4\beta_7$  and CCR9 (91, 93, 96-99).

A recent study has shown that exposure to RA can redirect immune responses elicited by subcutaneous vaccination of mice from skin-draining inguinal LNs to the gut (100). When present during priming in inguinal LNs, RA induced robust upregulation of gut-homing receptors CCR9 and  $\alpha 4\beta 7$  by further inducing autonomous RA production in inguinal LNs DCs. Importantly, RAsupplemented subcutaneous immunization generated a potent immune response in the small intestine that protected mice from cholera toxin-induced diarrhea and diminished bacterial loads in Peyer's Patches after oral infection with Salmonella. This is supported by another study which showed that presence of exogenous RA during systemic vaccination increased numbers of effector and memory CD8<sup>+</sup> T cells in mucosa-associated tissues that provided enhanced protection against mucosal viral challenges as well as increased central memory-like T cells in systemic sites that preferentially migrate to mucosal sites upon boosting (101).

Aside from producing RA, DCs can also internalize exogenous RA produced by other cells in the gut such as LP macrophages (102), mesenteric lymph node stromal cells (103) and gut epithelial cells (104). However, the contribution of RA from sources other than DCs towards the imprinting process is not fully established (105).

Studies in murine models have also demonstrated that GALT DCs are more effective at converting Vitamin A to RA than splenic DCs and other peripheral lymph node DCs, and are therefore more effective at inducing integrin  $\alpha_4\beta_7$  and CCR9 expression on T cells (91). In line with these observations, only CD103<sup>+</sup> DCs are able to induce the expression of  $\alpha_4\beta_7$  and CCR9, and were found to express higher levels of enzymes required for vitamin A metabolism compared to CD103<sup>-</sup> DCs (97, 98). Moreover, among these CD103<sup>+</sup> DCs, lamina propria DCs are the most effective at generating  $\alpha_4\beta_7^+$  CCR9<sup>+</sup> CD8<sup>+</sup> T cells compared to MLN DCs or PP DCs (98). The MLNs are believed to serve as the primary site where imprinting of gut homing specificity occurs as antigen-loaded DCs are carried into the MLNs via draining lymphatics (106-110). Further studies have shown that similar mechanisms involving vitamin A metabolism were also used to instruct regulatory T cells and B cells to become gut-tropic (99, 111-113).

# 5.5. Antigen-driven T cell trafficking

Although endowed with tissue-targeting homing properties that allow access to specific organs, such as the skin and gut, primed T-cells must patrol very large areas to locate antigen-rich tissue in order to exert their function. Together with the acquisition of homing receptors during activation differentiation and and non-specific inflammatory signals, additional antigen-driven mechanisms have been proposed, which orchestrate the targeted delivery of memory T cells to antigen-rich tissue. However, it is not clear to what extent the accumulation of specific T lymphocytes within parenchymal tissue is directly influenced by antigen recognition. In principle, several mechanisms could contribute to the accumulation of antigen-specific T cells at antigen-bearing sites: a), the trapping of antigen-specific T cells, for example upon TCR-triggered activation of integrin adhesion or effects on motility; b), local proliferation of antigen-specific cells; or c), a direct effect of antigen recognition on the recruitment of T cells. While trapping or local expansion may be operative during primary T cell responses, it is likely that these mechanisms 'per se' would be insufficient to achieve the efficacy and speed of specific T cell accumulation in target tissue in recall responses.

Antigen presentation by the endothelium has been repeatedly reported *in vitro* to directly contribute to the recruitment of antigen-specific T cells. Cognate recognition of ECs both in human and mice was shown to enhance T cell trans-endothelial migration. Cognate recognition of B7-deficient human and murine ECs was shown to enhance T-cell trans-endothelial migration without inducing unresponsiveness *in vitro* (114-116).

Similar mechanisms have been shown to sustain the recruitment of specific T cells to antigenic sites in vivo. Islet-specific homing by insulin-specific CD8<sup>+</sup> T cells was abrogated in mice lacking MHC class I expression, or in mice displaying impaired insulin peptide presentation by local endothelium due to lack of insulin secretion, suggesting that EC can cross-present tissue antigens to CD8<sup>+</sup> T cells (117). Similarly, homing of insulin-specific CD8<sup>+</sup> T cells to the islets of Langerhans during the onset of autoimmune diabetes in non-obese diabetic (NOD) mice in vivo was impaired in IFN-y-deficient NOD mice (118). In particular, T cell diapedesis was significantly diminished. This effect was reversible by treatment of the animals with recombinant IFN-7. Moreover, major histocompatibility complex (MHC) class II molecule expression by microvascular endothelium in the central nervous system precedes and is required for the formation of T cell infiltrates in EAE in guinea pigs (119). Finally, up-regulation of H2 molecules and HY antigen presentation by local vessels led to peritoneal recruitment of HY (male)-specific H2-D<sup>b</sup>-restricted  $CD8^+$ lymphocytes T cells in male, but not female mice (120). Intravital microscopy analysis revealed that antigen presentation by the endothelium selectively enhanced T cell diapedesis into the tissue, without affecting rolling and adhesion.

Crosstalk between TCR- and chemokine receptor-mediated signalling has recently been shown to be essential for T cell migration. CXCR4 signal transduction in human T cells requires the zeta-associated protein 70 (ZAP-70), a key element in TCR signalling (121). In addition, chemokine receptor expression is regulated by T cell activation (122). Chemokines contribute to antigen-specific T cells homing following cognate recognition of the endothelium *in vivo* (117, 123).

The relative contribution of antigen-specific and non-antigen-specific signals to memory T-cell recruitment is likely to be determined by the intensity of the inflammatory response. It is possible that TCR-mediated primed T-cell localization to antigenic sites may be essential to ensure efficient, rapid memory responses in the event of limited inflammatory signals. For example, insulin-specific H2-K<sup>d</sup>-restricted T cells are efficiently recruited to pancreatic islets of various H2-K<sup>d</sup>-positive mouse strains that are free of pre-existent inflammation (117). In contrast, severe inflammation or a pre-existing large antigen-specific T-cell repertoire (for example during direct alloresponses) may override the requirement for selective antigen-dependent T-cell recruitment (124).

# 5.6. Co-stimulatory molecules regulate T cell migration

Co-stimulatory signals such as those mediated by CD28 delivered to T cells in conjunction with TCR engagement are required to sustain T cell division, differentiation and survival (125). Negative co-stimulators (such as CTLA-4) counteract these effects thus promoting homeostatic mechanisms and preventing autoimmunity. These co-stimulators have been shown to regulate adhesion molecules activity and cytoskeletal rearrangement *in vitro* (126-129). *In vivo*, CD28-mediated signals promote the localization of T cells to target tissue following priming. A prominent feature of CD28-deficient immune responses is the inefficient localization of primed T cells to non-lymphoid antigenic site (130-132) and intact CD28 signalling is required for primed T cells to leave lymphoid tissue and migrate to antigenic sites following priming (133). TCR-transgenic T cells carrying a mutation in the cytoplasmic tail of CD28 (CD28<sup>Y170F</sup>) that abrogates phosphatidylinositol-3'-kinase (PI3K) recruitment without leading to defects in clonal expansion (134) failed to localize to target tissue following priming.

The mechanism by which CD28 facilitates migration of primed T cells to non-lymphoid tissue is unclear. CD28 does not appear to directly mediate adhesion (135), but may favor primed T cell migration to non-lymphoid tissue by inducing integrin mediated-adhesion (133). The long-term effect of CD28-mediated signals on T cell migration (133) suggests that additional mechanisms, such as transcriptional regulation of chemokine receptor expression (136), are likely to be involved.

Despite sharing adhesion-inducing and promigratory properties *in vitro* (137), CTLA-4-mediated signals lead to effects antagonistic to those induced by CD28 on T cell migration *in vivo*. CTLA-4 ligation reduced conjugate formation with cognate DCs and their retention in lymph nodes in response to antigen (138), suggesting that CTLA-4 engagement may limit the expansion of specific T cells by reducing their cumulative interactions with cognate DCs. In addition, tissue infiltration by a murine HY-specific H2-K<sup>k</sup>-restricted T cell clone was abrogated by CTLA-4 ligation (133), suggesting that CTLA-4 engagement can antagonize recruitment of primed T cells to target tissue mediated by antigen-induced signals.

In addition to CD28 and CTLA-4, a number of other costimulatory molecules have been implicated in the regulation of T-cell migration. For example, OX40/OX40 ligand interaction has been shown to be required for T-cell migration to germinal centres (139), and the inducible costimulatory molecule (ICOS) regulates human memory T-cell migration through tumor necrosis factor (TNF)- $\alpha$ -treated endothelial cells (140).

# 5.7. PI3K—mediated control of T cell migration

PI3K signaling mediates not only events downstream of TCR and CD28 (141, 142) leading to T cell division and differentiation, but also T cells responses to chemokines (143). It has recently been shown that both TCR- and CD28-driven T cell migration rely upon PI3K p110 $\delta$  activity (144, 145). Studies using T cells from mice expressing a catalytically inactive p110 $\delta$  isoform or treated with the p110 $\delta$  selective inhibitor, IC87114, revealed an essential role for this molecule in TCR-dependent localization of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells in a male antigen-specific transplantation model (144). Interestingly, and in support of previous findings (146), there was no defect in the p110 $\delta$  mutant mice of either normal constitutive trafficking or migratory response to chemokines. Recent evidence also strongly correlates CD28induced migration with PI3K (likely p110δ) signaling. TCR-transgenic mice carrying an ovalbumin-specific T cell receptor (OT-II) and a mutation in the cytoplasmic tail of CD28 that abrogates class I PI3K recruitment without leading to defects in clonal expansion (CD28<sup>Y170F</sup>) (134) were generated to allow discrimination of conventional costimulation-driven clonal-expansion from their ability to infiltrate antigenic tissue (OT-II/CD28<sup>Y170F</sup>). OT-II and OT-II/CD28<sup>Y170F</sup> naïve T cells proliferated equivalently following immunization with OVA<sub>323-339</sub> peptide. However, OT-II/CD28<sup>Y170F</sup> CD8<sup>+</sup> memory T cells failed to localize to target tissue upon antigen challenge. It has to be borne in mind that the PI3K binding motif in CD28 is also required for binding of the adaptors Grb2 and Gads and the involvement of PI3K is implied but not proven.

Naïve T cells express the adhesion molecule CD62L and the chemokine receptors CCR7 and sphingosine-1-phosphate receptor 1 (S1P1), which facilitate their trafficking to SLOs. Upon TCR engagement, the PI3K-AKT-mTOR axis promotes the transcriptional downregulation of CD62L, CCR7 and S1P1 via the inhibition of the transcription factor KLF2 (147, 148). Rapamycin-mediated inhibition of mTOR causes effector T cells to re-express KLF2, CD62L and CCR7 and home to SLOs where they are retained preventing elimination of target cells in the periphery (147, 148). In addition to the involvement in expression of CD62-L and CCR7, AKT, has also been implicated in F-actin polymerization and myosin assembly (149-152). Accordingly, PI3K (s) contribute to several aspects of the migratory machinery, including gradient sensing, signal amplification, actin reorganization and hence cell motility (153-155).

## 6. REGULATORY T CELL TRAFFICKING

Regulatory T cells ( $T_{regs}$ ) exert their function by suppressing T cell functional responses, thus preventing the development of autoimmunity (156, 157).  $T_{regs}$  are characterized by the constitutive expression of the transcription factor FoxP3, which confers them potent suppressive activity (158, 159). Humans with mutations affecting the FoxP3 gene suffer from fatal autoimmune diseases (IPEX: immune polyendocrine enteropathy Xlinked syndrome) (159). Similarly, mice with a spontaneous mutation in the FoxP3 gene – known as 'scurfy' mice - develop fatal autoimmune diseases affecting multiple organs (158). In IPEX patients and scurfy mice, chronically activated and self-reactive CD4<sup>+</sup> T cells are found to be responsible for the symptoms developed (160). These studies thus demonstrated the importance of  $T_{regs}$  in homeostasis in both animals and humans.

## 6.1. Naturally occurring regulatory T cells

Regulatory T cells were first described in mice by Sakaguchi and coworkers in 1995 as a subset of  $CD4^+$  T cells with a constitutive expression of IL-2 receptor alphachain CD25 (161). These naturally occurring cells develop in the thymus and constitute approximately 5-10% of all peripheral CD4<sup>+</sup> T cells in mice (162). They are anergic in nature and exhibit potent suppressive function both *in vivo*  and *in vitro* (162-164). Treg cells require activation signals via the T cell receptor; however, once activated their suppressor function is antigen non-specific (165).

 $\rm CD4^+\rm CD25^+$  regulatory T cells were isolated from human peripheral blood in 2001 (166, 167). Unlike mice, in which both  $\rm CD25^{high}$  and  $\rm CD25^{low}$  of the  $\rm CD4^+\rm CD25^+$ population exhibit suppressor functions, in humans only  $\rm CD4^+\rm CD25^{high}$  T cells are suppressive (166). Human  $\rm CD4^+\rm CD25^{high}$  regulatory T cells account for 1-2% of the total peripheral  $\rm CD4^+$  T cell population (166).

It must also be considered that high levels of CD25 and FoxP3 are transiently expressed by recently activated human T cells, which do not display suppressor functions (168, 169). Thus, a Treg-specific marker has yet to be identified. Despite this, markers important for the survival and the suppressive functions of  $T_{regs}$  have been identified such as the cytotoxic T lymphocytes antigen 4 (CTLA-4) and glucocorticoid-induced TNF-receptor-related protein (GITR) (170, 171).

#### 6.2. Induced regulatory T cells

Aside from naturally occurring regulatory T cells,  $T_{regs}$  can be induced from naïve CD4<sup>+</sup> CD25<sup>-</sup> T cells *in vitro* and *in vivo* (172-174). Thus far, the differentiation of naïve T cells into induced  $T_{regs}$  (i $T_{regs}$ ) *in vivo* has been documented in the murine intestine (96), inflamed lung (175), tumors (176) and transplanted tissues (177).

The possible underlying mechanisms of iTreg generation have also been explored in both humans and mice. *In vitro* generation of iTregs has been shown to be dependent on TGF- $\beta$  and IL-2 (172, 178). The Vitamin A metabolite RA also facilitates the generation of regulatory T cells mediated by TGF- $\beta$  following priming by DCs in the secondary lymphoid tissue (96, 99). In addition, studies have shown that only CD103<sup>+</sup> DCs in the small intestinal LPs and the MLNs are capable of generating FoxP3<sup>+</sup> T<sub>regs</sub> in the presence of TGF- $\beta$  and retinoic acid (96, 99). Regulatory T cells generated in the presence of retinoic acid also express fully functional gut-homing receptors  $\alpha_4\beta_7$  and CCR9 (113). Naturally occurring T<sub>regs</sub> and induced T<sub>regs</sub> have both been shown be anergic and able to suppress effector T cell responses *in vitro* and *in vivo* (179).

#### 6.3. Treg homing to secondary lymphoid organs

 $T_{regs}$  play a key role in tolerance induction and maintenance. Evidence suggests that Tregs-mediated immune suppression operates in both SLOs (180) and nonlymphoid tissue (181, 182). Appropriate trafficking and retention are therefore indispensable for  $T_{regs}$  to efficiently modulate immune response *in vivo*. Distinct chemokine and adhesion receptors may contribute to trafficking and retention of  $T_{regs}$  at sites where regulation is required (183-185). Naturally occurring  $T_{regs}$  express the adhesion molecule CD62L and the chemokine receptor CCR7, which facilitate their homing to the T-cell area in lymph nodes (180, 186, 187).

Migration to tissue-associated lymph nodes is required for their regulatory function.  $CD62L^+$  T<sub>rees</sub>, rather

than CD62L<sup>-</sup>  $T_{regs}$ , efficiently delay diabetes in prediabetic nonobese diabetic (NOD) mice (188) and protect from acute graft-versus-host disease (GVHD) (189). Similarly, CD62L-dependent  $T_{reg}$  homing to lymph nodes is necessary for the induction of transplantation tolerance (190). In addition  $T_{regs}$  from CCR7 knockout mice were inefficient in homing to lymph nodes and did not suppress antigeninduced activation of T cells (191).

To exert their regulatory function,  $T_{regs}$  need close physical contact with effector cells (192). Thus, effective suppression can only occur when migration and homing of  $T_{regs}$  run in parallel with those by effector cells. Evidence suggests that  $T_{regs}$  and effector T cells home to similar areas of the lymph nodes (193).

At the T-cell zone, naïve  $T_{regs}$  may recognize antigens and become activated (194). Upon activation,  $T_{regs}$  lose CCR7 expression and reduce CD62L expression (195, 196) and gain the expression of CXCR5, a chemokine receptor that promotes  $T_{regs}$  migration into germinal centres in response to CXCL13, where they regulate the magnitude and characteristics of antibody responses (197, 198).  $T_{regs}$ homing to lymph nodes therefore controls the induction phase of immune response (180, 193).

## 6.4. T<sub>reg</sub> homing to nonlymphoid tissue

The effector phase of immune response involves migration to and infiltration of antigen-rich non-lymphoid tissue by effector T cells. By migrating to non-lymphoid sites of inflammation T<sub>regs</sub> control effector immune responses (195, 199, 200). T cell trafficking to different tissues is determined by the combined expression of chemokine receptors and adhesion molecules on the cell surface (201). T<sub>regs</sub> activated in the lymph nodes draining a tissue acquire homing receptors that allow them to migrate back to the inflamed tissue drained by the lymph nodes. Like conventional T cells, the migratory properties of T<sub>regs</sub> are shaped by the tissue microenvironment and organresident dendritic cells during priming (111). For example,  $T_{regs}$  activated in MLNs and PPs acquire  $\alpha 4\beta 7$  and CCR9, which direct their trafficking to the gut. By contrast, Tregs activated in peripheral lymph nodes express CCR8, but not  $\alpha 4\beta 7$  and CCR9 (202). Interestingly, it has been shown that increased CLA or a4β7 expression by circulating human  $T_{\rm regs}$  is associated with reduced risk of skin or gut acute GVHD, respectively (203). Expression of tissue specific homing receptors depends on microenvironment-specific cues, such as retinoic acid produced by dendritic cells of gut tissue (91, 93).

In humans, expression of trafficking markers on circulating regulatory T cells is less well characterized. Recent studies have shown that a high frequency of the peripheral blood  $T_{regs}$  express the skin-homing receptors, CCR4, CLA. In contrast, CD103 and the gut-homing receptors  $\alpha_4\beta_7$  and CCR9 are found on a small number of circulating  $T_{regs}$  (204, 205). This observation raises the question of how regulatory T cells execute their suppressor functions in the gut (170). A possible explanation is that MAdCAM-1, the ligand of  $\alpha_4\beta_7$  is also capable of binding to CD62L found on regulatory T cells in humans and mice

(6, 199, 206). CD62L therefore may target  $T_{regs}$  to the MLNs and the PPs where they carry out suppressor functions (204).

Activated  $T_{regs}$  express  $\alpha E\beta7$ , which binds its ligand E-cadherin and allows efficient migration to- and retention within inflamed tissue to suppress the effector phase of immune response (195, 207).  $\alpha E\beta 7^+ T_{regs}$  display a heterogeneous pattern of tissue-specific homing receptors. A subset of activated T<sub>regs</sub> up-regulates CXCR4 expression and become responsive to SDF-1 (stromal-derived facor-1), enabling them to migrate to the bone marrow (208), where T<sub>regs</sub> can suppress immune responses (209-211). It has been described that more than 25% of  $CD4^+$  T cells are  $T_{regs}$  in bone marrow – as compared to 5-10% of CD4<sup>+</sup> T cells in the peripheral blood - of human and mice. Tregs exit from the bone marrow is achieved through granulocyte colonystimulating factor (G-CSF) and reduced expression of CXCL12, the ligand for CXCR4 (208). The bone marrow is a critical site of immunity as studies have shown that longlived, antibody-secreting plasma cells (211) and functional memory T cells (210, 212) reside in this organ. Thus, it appears that T<sub>regs</sub> are actively, rather than passively, recruited and retained in the bone marrow to regulate immune responses during homeostasis.

 $T_{regs}$  must migrate to transplanted organs to effectively suppress intragraft anti-donor immune response. It has been shown that T effector cells with high avidity for donor antigens home to transplanted heart to mediate transplant rejection (213). Intragraft  $T_{regs}$  have been associated with tolerance induction.  $T_{regs}$  with unique chemokine profile have been shown to migrate to different tissue grafts. The recruitment of Tregs in heart allograft of tolerant mice is associated with CCR4 expression (182). Tregs migration into isl*et al*lografts is dependent on the chemokine receptors CCR2, CCR4, CCR5 and P- and Eselectin ligands expression (214). Wysocki and colleagues have shown that CCR5 plays an important role in  $T_{regs}$ recruitment to both lymphoid tissues and graft versus host disease (GVHD) target organs (215).

It is thought that  $T_{regs}$  share many homing receptors with conventional T cells. However,  $T_{regs}$  express more receptors associated with homing to non-lymphoid tissue, such as CXCR6, CCR5, CCR6 and CCR8 emphasizing the requirement for their migration to control inflammation at the effector site (202).

A study by Tomura *et al.* showed that in steadystate  $T_{regs}$  constitutively migrated from the skin to draining LNs in mice. Furthermore, they demonstrated that not only does skin inflammation exacerbate LN-directed  $T_{reg}$ homing, but it also triggered reverse circulation of  $T_{regs}$ from LNs to skin, whereby these cells contribute to regulation of the immune response (216).

Emerging evidence suggests that  $T_{regs}$  trafficking and compartmentalization can be modulated allowing efficient tissue targeting after *ex vivo* expansion. Siewert and colleagues have shown that  $T_{regs}$  can be configured both *in vitro* and *in vivo* with organ-selective homing properties allowing efficient migration into target tissue. This suggests that modulation of  $T_{regs}$  designed to serve for therapeutic purposes with specific homing properties is feasible for adoptive T cell therapy (111). Moreover,  $\alpha 4\beta 7$ + regulatory T cells generated *in vitro* are also able to effectively clear acute inflammation in the small intestine when transferred into the diseased animals (217).

## 7. CONCLUDING REMARKS

The immune system is unique in representing a network of interacting cells of enormous complexity and vet being based on single cells travelling around the body. Every decade of immunological research appears to reveal novel functional subsets of T cells. How this expanding universe of specialists becomes co-ordinated and appropriately targeted to the hot-spots of immunoreactivity would have remained a mystery if, at the same time, our knowledge of the mechanisms of cell trafficking had not greatly improved. Co-operating adhesion molecules and chemokine receptors equip the migrating cells with an almost unlimited combinatorial diversity which allows them to recognize the signatures defining tissues and compartments, to distinguish different inflammatory processes depending on the kind of triggers, site of inflammation, or involved cell populations and so on. Monitoring of the migration of T-cell subsets associated with immune-mediated diseases may prove to be essential in allowing us to understand pathogenic mechanisms, to design prognostic and therapeutic tools and to predict therapeutic responses. If these goals are to be achieved, we must address the many unanswered questions.

Keywords: homing receptors; T lymphocytes; T-cell homing, T cell migration

## 8. ACKOWLEDGEMENTS

F.M.M-B. is supported by the British Heart Foundation, the Medical Research Council of the UK and the Gates Foundation. C.M. is supported by the British Heart Foundation.

#### 9. REFERENCES

1. G. Wiedle, D. Dunon, and B.A. Imhof, Current concepts in lymphocyte homing and recirculation. *Crit Rev Clin Lab Sci* 38, 1-31(2001)

2. F.M. Marelli-Berg, H. Fu, F. Vianello, K. Tokoyoda, and A. Hamann, Memory T-cell trafficking: new directions for busy commuters. *Immunology* 130, 158-65(2010)

3. E.C. Butcher, M. Williams, K. Youngman, L. Rott, and M. Briskin, Lymphocyte trafficking and regional immunity. *Adv Immunol* 72, 209-53 (1999)

4. M. Lewis, J.F. Tarlton, and S. Cose, Memory versus naive T-cell migration. *Immunol Cell Biol* 86, 226-31 (2008)

5. E.C. Butcher, and L.J. Picker, Lymphocyte homing and homeostasis. *Science* 272, 60-6 (1996)

6. L.J. Picker, and E.C. Butcher, Physiological and molecular mechanisms of lymphocyte homing. *Annu Rev Immunol* 10, 561-91 (1992)

7. C. Berlin, E.L. Berg, M.J. Briskin, D.P. Andrew, P.J. Kilshaw, B. Holzmann, I.L. Weissman, A. Hamann, and E.C. Butcher, Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. *Cell* 74, 185-95 (1993)

8. Y. Reiss, A.E. Proudfoot, C.A. Power, J.J. Campbell, and E.C. Butcher, CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. *J Exp Med* 194, 1541-7 (2001)

9. E.L. Berg, T. Yoshino, L.S. Rott, M.K. Robinson, R.A. Warnock, T.K. Kishimoto, L.J. Picker, and E.C. Butcher, The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. *J Exp Med* 174, 1461-6 (1991)

10. C.A. Janeway, Immunobiology : the immune system in health and disease, Garland Science, New York ; London, 2005.

11. K. Ley, and G.S. Kansas, Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. *Nat Rev Immunol* 4, 325-35 (2004)

12. K. Yonekawa, and J.M. Harlan, Targeting leukocyte integrins in human diseases. *J Leukoc Biol* 77, 129-40 (2005)

13. W.J. Grossman, J.W. Verbsky, W. Barchet, M. Colonna, J.P. Atkinson, and T.J. Ley, Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity* 21, 589-601 (2004)

14. M.S. Diamond, and T.A. Springer, The dynamic regulation of integrin adhesiveness. *Curr Biol* 4, 506-17 (1994)

15. B. Johnston, and E.C. Butcher, Chemokines in rapid leukocyte adhesion triggering and migration. *Semin Immunol* 14, 83-92 (2002)

16. M. Fabbri, E. Bianchi, L. Fumagalli, and R. Pardi, Regulation of lymphocyte traffic by adhesion molecules. *Inflamm Res* 48, 239-46 (1999)

17. L.M. Ebert, P. Schaerli, and B. Moser, Chemokinemediated control of T cell traffic in lymphoid and peripheral tissues. *Mol Immunol* 42, 799-809 (2005)

18. B. Moser, and K. Willimann, Chemokines: role in inflammation and immune surveillance. *Ann Rheum Dis* 63 Suppl 2, ii84-ii89 (2004)

19. I.M. Roitt, J. Brostoff, and D.K. Male, Immunology, Mosby-Wolfe, St. Louis, Mo., 1998.

20. T. Garrood, L. Lee, and C. Pitzalis, Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways. *Rheumatology* (Oxford) 45, 250-60 (2006)

21. S. Nourshargh, and F.M. Marelli-Berg, Transmigration through venular walls: a key regulator of leukocyte phenotype and function. *Trends Immunol* 26, 157-65 (2005)

22. B. Engelhardt, and H. Wolburg, Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? *Eur J Immunol* 34, 2955-63 (2004)

23. H. Wolburg, K. Wolburg-Buchholz, and B. Engelhardt, Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. *Acta Neuropathol* 109, 181-90 (2005)

24. J. Millan, L. Hewlett, M. Glyn, D. Toomre, P. Clark, and A.J. Ridley, Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. *Nat Cell Biol* 8, 113-23 (2006)

25. D. Vestweber, Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. *Immunol Rev* 218, 178-96 (2007)

26. Y. Shimizu, G.A. van Seventer, K.J. Horgan, and S. Shaw, Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. *Immunol Rev* 114, 109-43 (1990)

27. C.R. Mackay, Immunological memory. *Adv Immunol* 53, 217-65 (1993)

28. E.S. Vitetta, M.T. Berton, C. Burger, M. Kepron, W.T. Lee, and X.M. Yin, Memory B and T cells. *Annu Rev Immunol* 9, 193-217 (1991)

29. J. Sprent, T and B memory cells. Cell 76, 315-22 (1994)

30. J. Garcia de Tena, L. Manzano, J.C. Leal, E. San Antonio, V. Sualdea, and M. Alvarez-Mon, Distinctive pattern of cytokine production and adhesion molecule expression in peripheral blood memory CD4+ T cells from patients with active Crohn's disease. *J Clin Immunol* 26, 233-42 (2006)

31. U.H. von Andrian, and T.R. Mempel, Homing and cellular traffic in lymph nodes. *Nat Rev Immunol* 3, 867-78 (2003)

32. C.R. Mackay, W.L. Marston, and L. Dudler, Naive and memory T cells show distinct pathways of lymphocyte recirculation. *J Exp Med* 171, 801-17 (1990)

33. D. Vestweber, Lymphocyte trafficking through blood and lymphatic vessels: more than just selectins, chemokines and integrins. *Eur J Immunol* 33, 1361-4 (2003)

34. W. Weninger, H.S. Carlsen, M. Goodarzi, F. Moazed, M.A. Crowley, E.S. Baekkevold, L.L. Cavanagh, and U.H. von Andrian, Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. *J Immunol* 170, 4638-48 (2003)

35. C. Moussion, and J.P. Girard, Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. *Nature* 479, 542-6 (2011)

36. P.R. Streeter, B.T. Rouse, and E.C. Butcher, Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. *J Cell Biol* 107, 1853-62 (1988)

37. O. Williams, R. Tarazona, A. Wack, N. Harker, K. Roderick, and D. Kioussis, Interactions with multiple peptide ligands determine the fate of developing thymocytes. *Proc Natl Acad Sci U S A* 95, 5706-11 (1998)

38. E.S. Baekkevold, T. Yamanaka, R.T. Palframan, H.S. Carlsen, F.P. Reinholt, U.H. von Andrian, P. Brandtzaeg, and G. Haraldsen, The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. *J Exp Med* 193, 1105-12 (2001)

39. R.F. Bargatze, M.A. Jutila, and E.C. Butcher, Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. *Immunity* 3, 99-108 (1995)

40. D.J. Campbell, C.H. Kim, and E.C. Butcher, Chemokines in the systemic organization of immunity. *Immunol Rev* 195, 58-71 (2003)

41. D.J. Erle, M.J. Briskin, E.C. Butcher, A. Garcia-Pardo, A.I. Lazarovits, and M. Tidswell, Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. *J Immunol* 153, 517-28 (1994)

42. L.S. Rott, M.J. Briskin, D.P. Andrew, E.L. Berg, and E.C. Butcher, A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. *J Immunol* 156, 3727-36 (1996)

43. N. Wagner, J. Lohler, T.F. Tedder, K. Rajewsky, W. Muller, and D.A. Steeber, L-selectin and beta7 integrin synergistically mediate lymphocyte migration to mesenteric lymph nodes. *Eur J Immunol* 28, 3832-9 (1998)

44. J. Sprent, Antigen-induced selective sequestration of T lymphocytes: role of the major histocompatibility complex. *Monogr Allergy* 16, 233-44 (1980)

45. F. Sallusto, J. Geginat, and A. Lanzavecchia, Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol* 22, 745-63 (2004)

46. F. Sallusto, D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401, 708-12 (1999)

47. N. Manjunath, P. Shankar, J. Wan, W. Weninger, M.A. Crowley, K. Hieshima, T.A. Springer, X. Fan, H. Shen, J. Lieberman, and U.H. von Andrian, Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. *J Clin Invest* 108, 871-8 (2001)

48. U.H. von Andrian, and C.R. Mackay, T-cell function and migration. Two sides of the same coin. *N Engl J Med* 343, 1020-34 (2000)

49. J. Sprent, and S.R. Webb, Intrathymic and extrathymic clonal deletion of T cells. *Curr Opin Immunol* 7, 196-205 (1995)

50. D. Masopust, V. Vezys, A.L. Marzo, and L. Lefrancois, Preferential localization of effector memory cells in nonlymphoid tissue. *Science* 291, 2413-7 (2001)

51. G. Guarda, M. Hons, S.F. Soriano, A.Y. Huang, R. Polley, A. Martin-Fontecha, J.V. Stein, R.N. Germain, A. Lanzavecchia, and F. Sallusto, L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. *Nat Immunol* 8, 743-52 (2007)

52. S.K. Bromley, S.Y. Thomas, and A.D. Luster, Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. *Nat Immunol* 6, 895-901 (2005)

53. R. Pappu, S.R. Schwab, I. Cornelissen, J.P. Pereira, J.B. Regard, Y. Xu, E. Camerer, Y.W. Zheng, Y. Huang, J.G. Cyster, and S.R. Coughlin, Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. *Science* 316, 295-8 (2007)

54. J.R. Mora, and U.H. von Andrian, T-cell homing specificity and plasticity: new concepts and future challenges. *Trends Immunol* 27, 235-43 (2006)

55. W. Weninger, M.A. Crowley, N. Manjunath, and U.H. von Andrian, Migratory properties of naive, effector, and memory CD8(+) T cells. *J Exp Med* 194, 953-66 (2001)

56. S. Shetty, C.J. Weston, Y.H. Oo, N. Westerlund, Z. Stamataki, J. Youster, S.G. Hubscher, M. Salmi, S. Jalkanen, P.F. Lalor, and D.H. Adams, Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. *J Immunol* 186, 4147-55 (2011)

57. R.W. Groves, M.H. Allen, J.N. Barker, D.O. Haskard, and D.M. MacDonald, Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. *Br J Dermatol* 124, 117-23 (1991)

58. X. Jiang, J.J. Campbell, and T.S. Kupper, Embryonic trafficking of gammadelta T cells to skin is dependent on E/P selectin ligands and CCR4. *Proc Natl Acad Sci U S A* 107, 7443-8 (2010)

59. J. Morales, B. Homey, A.P. Vicari, S. Hudak, E. Oldham, J. Hedrick, R. Orozco, N.G. Copeland, N.A. Jenkins, L.M. McEvoy, and A. Zlotnik, CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. *Proc Natl Acad Sci US A* 96, 14470-5 (1999)

60. Y Jin , M Xia , A Sun , CM Saylor , N Xiong, CCR10 is important for the development of skin-specific gammadeltaT cells by regulating their migration and location. *J Immunol*, 185 (10): p. 5723-31 (2010)

61. A. Batra, A.C. Smith, J. Feehally, and J. Barratt, T-cell homing receptor expression in IgA nephropathy. *Nephrol Dial Transplant* 22, (2007) 2540-8.

62. L. Lefrancois, C.M. Parker, S. Olson, W. Muller, N. Wagner, M.P. Schon, and L. Puddington, The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med 189, 1631-8 (1999)

63. T. Schweighoffer, Y. Tanaka, M. Tidswell, D.J. Erle, K.J. Horgan, G.E. Luce, A.I. Lazarovits, D. Buck, and S. Shaw, Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. *J Immunol* 151, 717-29 (1993)

64. M. Briskin, D. Winsor-Hines, A. Shyjan, N. Cochran, S. Bloom, J. Wilson, L.M. McEvoy, E.C. Butcher, N. Kassam, C.R. Mackay, W. Newman, and D.J. Ringler, Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. *Am J Pathol* 151, 97-110 (1997)

65. N. Wagner, J. Lohler, E.J. Kunkel, K. Ley, E. Leung, G. Krissansen, K. Rajewsky, and W. Muller, Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. *Nature* 382, 366-70 (1996)

66. O. Pabst, R. Forster, M. Lipp, H. Engel, and H.H. Arnold, NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. *EMBO J* 19, 2015-23 (2000)

67. H. Stenstad, M. Svensson, H. Cucak, K. Kotarsky, and W.W. Agace, Differential homing mechanisms regulate regionalized effector CD8alphabeta+ T cell accumulation within the small intestine. *Proc Natl Acad Sci U S A* 104, 10122-7 (2007)

68. E.J. Kunkel, J.J. Campbell, G. Haraldsen, J. Pan, J. Boisvert, A.I. Roberts, E.C. Ebert, M.A. Vierra, S.B. Goodman, M.C. Genovese, A.J. Wardlaw, H.B. Greenberg, C.M. Parker, E.C. Butcher, D.P. Andrew, and W.W. Agace, Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an

organizing principle in regional immunity. J Exp Med 192, 761-8 (2000)

69. B.A. Zabel, W.W. Agace, J.J. Campbell, H.M. Heath, D. Parent, A.I. Roberts, E.C. Ebert, N. Kassam, S. Qin, M. Zovko, G.J. LaRosa, L.L. Yang, D. Soler, E.C. Butcher, P.D. Ponath, C.M. Parker, and D.P. Andrew, Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. *J Exp Med* 190, 1241-56 (1999)

70. M. Nishimura, Y. Kuboi, K. Muramoto, T. Kawano, and T. Imai, Chemokines as novel therapeutic targets for inflammatory bowel disease. *Ann N Y Acad Sci* 1173, 350-6 (2009)

71. C. Koenecke, and R. Forster, CCR9 and inflammatory bowel disease. *Expert Opin Ther Targets* 13, 297-306 (2009)

72. E.J. Kunkel, D.J. Campbell, and E.C. Butcher, Chemokines in lymphocyte trafficking and intestinal immunity. *Microcirculation* 10, 313-23 (2003)

73. B. Johansson-Lindbom, M. Svensson, M.A. Wurbel, B. Malissen, G. Marquez, and W. Agace, Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. *J Exp Med* 198, 963-9 (2003)

74. H. Stenstad, A. Ericsson, B. Johansson-Lindbom, M. Svensson, J. Marsal, M. Mack, D. Picarella, D. Soler, G. Marquez, M. Briskin, and W.W. Agace, Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. *Blood* 107, 3447-54 (2006)

75. J. Marsal, M. Svensson, A. Ericsson, A.H. Iranpour, L. Carramolino, G. Marquez, and W.W. Agace, Involvement of CCL25 (TECK) in the generation of the murine small-intestinal CD8alpha alpha+CD3+ intraepithelial lymphocyte compartment. *Eur J Immunol* 32, 3488-97 (2002)

76. K.A. Papadakis, J. Prehn, V. Nelson, L. Cheng, S.W. Binder, P.D. Ponath, D.P. Andrew, and S.R. Targan, The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. *J Immunol* 165, 5069-76 (2000)

77. M.A. Wurbel, J.M. Philippe, C. Nguyen, G. Victorero, T. Freeman, P. Wooding, A. Miazek, M.G. Mattei, M. Malissen, B.R. Jordan, B. Malissen, A. Carrier, and P. Naquet, The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. *Eur J Immunol* 30, 262-71 (2000)

78. N. Hosoe, S. Miura, C. Watanabe, Y. Tsuzuki, R. Hokari, T. Oyama, Y. Fujiyama, H. Nagata, and H. Ishii, Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. *Am J Physiol Gastrointest Liver Physiol* 286, G458-66 (2004)

79. C.S. Bonder, M.U. Norman, M.G. Swain, L.D. Zbytnuik, J. Yamanouchi, P. Santamaria, M. Ajuebor, M. Salmi, S. Jalkanen, and P. Kubes, Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. *Immunity* 23, 153-63 (2005)

80. K. Arai, T. Iiai, M. Nakayama, K. Hasegawa, K. Sato, K. Ohtsuka, H. Watanabe, T. Hanyu, H.E. Takahashi, and T. Abo, Adhesion molecules on intermediate TCR cells. I. Unique expression of adhesion molecules, CD44+ L-selectin-, on intermediate TCR cells in the liver and the modulation of their adhesion by hyaluronic acid. *Immunology* 84, 64-71 (1995)

81. S. Ribeiro, and R. Horuk, The clinical potential of chemokine receptor antagonists. *Pharmacol Ther* 107, 44-58 (2005)

82. P. Loetscher, M. Uguccioni, L. Bordoli, M. Baggiolini, B. Moser, C. Chizzolini, and J.M. Dayer, CCR5 is characteristic of Th1 lymphocytes. *Nature* 391, 344-5 (1998)

83. S.A. Luther, and J.G. Cyster, Chemokines as regulators of T cell differentiation. *Nat Immunol* 2, 102-7 (2001)

84. D.J. Carr, J. Ash, T.E. Lane, and W.A. Kuziel, Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1. *J Gen Virol* 87, 489-99 (2006)

85. M. Locati, and P.M. Murphy, Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. *Annu Rev Med* 50, 425-40 (1999)

86. T.C. Dawson, M.A. Beck, W.A. Kuziel, F. Henderson, and N. Maeda, Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. *Am J Pathol* 156, 1951-9 (2000)

87. J.R. Mora, M.R. Bono, N. Manjunath, W. Weninger, L.L. Cavanagh, M. Rosemblatt, and U.H. Von Andrian, Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. *Nature* 424, 88-93 (2003)

88. A.J. Stagg, M.A. Kamm, and S.C. Knight, Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. *Eur J Immunol* 32, 1445-54 (2002)

89. D.J. Campbell, and E.C. Butcher, Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. *J Exp Med* 195, 135-41 (2002)

90. H. Sigmundsdottir, J. Pan, G.F. Debes, C. Alt, A. Habtezion, D. Soler, and E.C. Butcher, DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. *Nat Immunol* 8, 285-93 (2007)

91. M. Iwata, A. Hirakiyama, Y. Eshima, H. Kagechika, C. Kato, and S.Y. Song, Retinoic acid imprints gut-homing specificity on T cells. *Immunity* 21, 527-38 (2004)

92. T. Moore, Vitamin A and carotene: The absence of the liver oil vitamin A from carotene. VI. The conversion of carotene to vitamin A in vivo. *Biochem J* 24, 692-702 (1930)

93. H. Sigmundsdottir, and E.C. Butcher, Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. *Nat Immunol* 9, 981-7 (2008)

94. J.L. Napoli, Interactions of retinoid binding proteins and enzymes in retinoid metabolism. *Biochim Biophys Acta* 1440, 139-62 (1999)

95. G. Duester, Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. *Eur J Biochem* 267, 4315-24 (2000)

96. J.L. Coombes, K.R. Siddiqui, C.V. Arancibia-Carcamo, J. Hall, C.M. Sun, Y. Belkaid, and F. Powrie, A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. *J Exp Med* 204, 1757-64 (2007)

97. E. Jaensson, H. Uronen-Hansson, O. Pabst, B. Eksteen, J. Tian, J.L. Coombes, P.L. Berg, T. Davidsson, F. Powrie, B. Johansson-Lindbom, and W.W. Agace, Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. *J Exp Med* 205, 2139-49 (2008)

98. B. Johansson-Lindbom, M. Svensson, O. Pabst, C. Palmqvist, G. Marquez, R. Forster, and W.W. Agace, Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. *J Exp Med* 202, 1063-73 (2005)

99. C.M. Sun, J.A. Hall, R.B. Blank, N. Bouladoux, M. Oukka, J.R. Mora, and Y. Belkaid, Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. *J Exp Med* 204, 1775-85 (2007)

100. SI Hammerschmidt , M Friedrichsen , J Boelter , M Lyszkiewicz , E Kremmer , O Pabst , R Förster, Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice. *J Clin Invest*, 121 (8): p. 3051-61 (2011)

101. X Tan , JL Sande , JS Pufnock , JN Blattman , PD Greenberg, Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge. *J Virol*, 85 (16): p. 8316-27 (2011)

102. T.L. Denning, Y.C. Wang, S.R. Patel, I.R. Williams, and B. Pulendran, Lamina propria macrophages and dendritic cells differentially induce regulatory and

interleukin 17-producing T cell responses. Nat Immunol 8, 1086-94 (2007)

103. S.I. Hammerschmidt, M. Ahrendt, U. Bode, B. Wahl, E. Kremmer, R. Forster, and O. Pabst, Stromal mesenteric lymph node cells are essential for the generation of guthoming T cells in vivo. *J Exp Med* 205, 2483-90 (2008)

104. A. Lampen, S. Meyer, T. Arnhold, and H. Nau, Metabolism of vitamin A and its active metabolite all-transretinoic acid in small intestinal enterocytes. *J Pharmacol Exp Ther* 295, 979-85 (2000)

105. S.C. Ng, M.A. Kamm, A.J. Stagg, and S.C. Knight, Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. *Inflamm Bowel Dis* 16, 1787-807 (2010)

106. R. Forster, O. Pabst, and G. Bernhardt, Homeostatic chemokines in development, plasticity, and functional organization of the intestinal immune system. *Semin Immunol* 20, 171-80 (2008).

107. J.L. Coombes, and F. Powrie, Dendritic cells in intestinal immune regulation. *Nat Rev Immunol* 8, 435-46 (2008)

108. A.J. Macpherson, and T. Uhr, Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science* 303, 1662-5 (2004)

109. A.M. Mowat, Anatomical basis of tolerance and immunity to intestinal antigens. *Nat Rev Immunol* 3, 331-41 (2003)

110. V. Malmstrom, D. Shipton, B. Singh, A. Al-Shamkhani, M.J. Puklavec, A.N. Barclay, and F. Powrie, CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. *J Immunol* 166, 6972-81(2001)

111. C. Siewert, A. Menning, J. Dudda, K. Siegmund, U. Lauer, S. Floess, D.J. Campbell, A. Hamann, and J. Huehn, Induction of organ-selective CD4+ regulatory T cell homing. *Eur J Immunol* 37, 978-89 (2007)

112. J.R. Mora, M. Iwata, B. Eksteen, S.Y. Song, T. Junt, B. Senman, K.L. Otipoby, A. Yokota, H. Takeuchi, P. Ricciardi-Castagnoli, K. Rajewsky, D.H. Adams, and U.H. von Andrian, Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Science* 314, 1157-60 (2006)

113. S.G. Kang, H.W. Lim, O.M. Andrisani, H.E. Broxmeyer, and C.H. Kim, Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. *J Immunol* 179, 3724-33 (2007)

114. J.E. Greening, T.I. Tree, K.T. Kotowicz, A.G. van Halteren, B.O. Roep, N.J. Klein, and M. Peakman, Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. *Diabetes* 52, 717-25 (2003)

115. F.M. Marelli-Berg, L. Frasca, L. Weng, G. Lombardi, and R.I. Lechler, Antigen recognition influences transendothelial migration of CD4+ T cells. *J Immunol* 162, 696-703 (1999)

116. T.D. Manes, and J.S. Pober, Antigen presentation by human microvascular endothelial cells triggers ICAM-1dependent transendothelial protrusion by, and fractalkinedependent transendothelial migration of, effector memory CD4+ T cells. *J Immunol* 180, 8386-92 (2008)

117. A.Y. Savinov, F.S. Wong, A.C. Stonebraker, and A.V. Chervonsky, Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. *J Exp Med* 197, 643-56 (2003)

118. A.Y. Savinov, F.S. Wong, and A.V. Chervonsky, IFNgamma affects homing of diabetogenic T cells. *J Immunol* 167, 6637-43 (2001)

119. R.A. Sobel, B.W. Blanchette, A.K. Bhan, and R.B. Colvin, The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. *J Immunol* 132, 2402-7 (1984)

120. F.M. Marelli-Berg, M.J. James, J. Dangerfield, J. Dyson, M. Millrain, D. Scott, E. Simpson, S. Nourshargh, and R.I. Lechler, Cognate recognition of the endothelium induces HYspecific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. *Blood* 103, 3111-6 (2004)

121. M. Ticchioni, C. Charvet, N. Noraz, L. Lamy, M. Steinberg, A. Bernard, and M. Deckert, Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration. *Blood* 99, 3111-8 (2002)

122. M. Iwasaki, T. Mukai, P. Gao, W.R. Park, C. Nakajima, M. Tomura, H. Fujiwara, and T. Hamaoka, A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4(+) and CD8(+) T cells. *Eur J Immunol* 31, 2411-20 (2001)

123. M. Svensson, J. Marsal, A. Ericsson, L. Carramolino, T. Broden, G. Marquez, and W.W. Agace, CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. *J Clin Invest* 110, 1113-21 (2002)

124. D. Kreisel, A.M. Krasinskas, A.S. Krupnick, A.E. Gelman, K.R. Balsara, S.H. Popma, M. Riha, A.M. Rosengard, L.A. Turka, and B.R. Rosengard, Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. *J Immunol* 173, 3027-34 (2004)

125. M.L. Alegre, K.A. Frauwirth, and C.B. Thompson, T-cell regulation by CD28 and CTLA-4. *Nat Rev Immunol* 1, 220-8 (2001)

126. Y. Shimizu, G.A. van Seventer, E. Ennis, W. Newman, K.J. Horgan, and S. Shaw, Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. *J Exp Med* 175, 577-82 (1992)

127. S.M. Turcovski-Corrales, R.G. Fenton, G. Peltz, and D.D. Taub, CD28:B7 interactions promote T cell adhesion. *Eur J Immunol* 25, 3087-93 (1995)

128. T. Zell, S.W. Hunt, 3rd, J.L. Mobley, L.D. Finkelstein, and Y. Shimizu, CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. *J Immunol* 156, 883-6 (1996)

129. T Zell, SW 3rd Hunt, JL Mobley, LD Finkelstein, Y Shimizu, CD28-mediated up-regulation of beta 1-integrin adhesion involves phosphatidylinositol 3-kinase. *J Immunol* 156: p. 883-6 (1996)

130. T.T. Chang, C. Jabs, R.A. Sobel, V.K. Kuchroo, and A.H. Sharpe, Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. *J Exp Med* 190, 733-40 (1999)

131. A.M. Girvin, M.C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J.A. Bluestone, and S.D. Miller, A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. *J Immunol* 164, 136-43 (2000)

132. B. Salomon, and J.A. Bluestone, Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol* 19, 225-52 (2001)

133. V. Mirenda, S.J. Jarmin, R. David, J. Dyson, D. Scott, Y. Gu, R.I. Lechler, K. Okkenhaug, and F.M. Marelli-Berg, Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. *Blood* 109, 2968-77 (2007)

134. K. Okkenhaug, L. Wu, K.M. Garza, J. La Rose, W. Khoo, B. Odermatt, T.W. Mak, P.S. Ohashi, and R. Rottapel, A point mutation in CD28 distinguishes proliferative signals from survival signals. *Nat Immunol* 2, 325-32 (2001)

135. S.K. Bromley, W.R. Burack, K.G. Johnson, K. Somersalo, T.N. Sims, C. Sumen, M.M. Davis, A.S. Shaw, P.M. Allen, and M.L. Dustin, The immunological synapse. *Annu Rev Immunol* 19, 375-96 (2001)

136. L.S. Walker, A. Gulbranson-Judge, S. Flynn, T. Brocker, C. Raykundalia, M. Goodall, R. Forster, M. Lipp, and P. Lane, Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. *J Exp Med* 190, 1115-22 (1999)

137. B. Wei, S. da Rocha Dias, H. Wang, and C.E. Rudd, CTL-associated antigen-4 ligation induces rapid T cell polarization that depends on phosphatidylinositol 3-kinase, Vav-1, Cdc42, and myosin light chain kinase. *J Immunol* 179, 400-8 (2007)

138. H. Schneider, J. Downey, A. Smith, B.H. Zinselmeyer, C. Rush, J.M. Brewer, B. Wei, N. Hogg, P. Garside, and C.E. Rudd, Reversal of the TCR stop signal by CTLA-4. Science 313, 1972-5 (2006)

139. L.S. Walker, A. Gulbranson-Judge, S. Flynn, T. Brocker, C. Raykundalia, M. Goodall, R. Forster, M. Lipp, and P. Lane, Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. *J Exp Med* 190, 1115-22 (1999)

140. N. Okamoto, Y. Nukada, K. Tezuka, K. Ohashi, K. Mizuno, and T. Tsuji, AILIM/ICOS signaling induces T-cell migration/polarization of memory/effector T-cells. *Int Immunol* 16, 1515-22 (2004)

141. R.V. Parry, G.C. Whittaker, M. Sims, C.E. Edmead, M.J. Welham, and S.G. Ward, Ligation of CD28 stimulates the formation of a multimeric signaling complex involving grb-2-associated binder 2 (gab2), SRC homology phosphatase-2, and phosphatidylinositol 3-kinase: evidence that negative regulation of CD28 signaling requires the gab2 pleckstrin homology domain. *J Immunol* 176, 594-602 (2006)

142. K. Okkenhaug, and B. Vanhaesebroeck, PI3K in lymphocyte development, differentiation and activation. *Nat Rev Immunol* 3, 317-30 (2003)

143. S.G. Ward, and F.M. Marelli-Berg, Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation. *Biochem J* 418, 13-27 (2009)

144. S.J. Jarmin, R. David, L. Ma, J.G. Chai, H. Dewchand, A. Takesono, A.J. Ridley, K. Okkenhaug, and F.M. Marelli-Berg, T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice. *J Clin Invest* 118, 1154-64 (2008)

145. V. Mirenda, S.J. Jarmin, R. David, J. Dyson, D. Scott, Y. Gu, R.I. Lechler, K. Okkenhaug, and F.M. Marelli-Berg, Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. *Blood* 109, 2968-77.

146. K. Reif, K. Okkenhaug, T. Sasaki, J.M. Penninger, B. Vanhaesebroeck, and J.G. Cyster, Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. *J Immunol* 173, (2004) 2236-40 (2007)

147. D. Finlay, and D.A. Cantrell, Metabolism, migration and memory in cytotoxic T cells. *Nat Rev Immunol* 11, 109-17 (2011) 148. L.V. Sinclair, D. Finlay, C. Feijoo, G.H. Cornish, A. Gray, A. Ager, K. Okkenhaug, T.J. Hagenbeek, H. Spits, and D.A. Cantrell, Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. *Nat Immunol* 9, 513-21 (2008)

149. V. Kolsch, P.G. Charest, and R.A. Firtel, The regulation of cell motility and chemotaxis by phospholipid signaling. *J Cell Sci* 121, 551-9 (2008)

150. J. Li, B.A. Ballif, A.M. Powelka, J. Dai, S.P. Gygi, and V.W. Hsu, Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling of integrin beta1 to control cell migration. *Dev Cell* 9, 663-73 (2005)

151. A. Enomoto, H. Murakami, N. Asai, N. Morone, T. Watanabe, K. Kawai, Y. Murakumo, J. Usukura, K. Kaibuchi, and M. Takahashi, Akt/PKB regulates actin organization and cell motility via Girdin/APE. *Dev Cell* 9, 389-402 (2005)

152. V. Stambolic, and J.R. Woodgett, Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. *Trends Cell Biol* 16, 461-6 (2006)

153. A.J. Ridley, M.A. Schwartz, K. Burridge, R.A. Firtel, M.H. Ginsberg, G. Borisy, J.T. Parsons, and A.R. Horwitz, Cell migration: integrating signals from front to back. *Science* 302, 1704-9 (2003)

154. S. Merlot, and R.A. Firtel, Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. *J Cell Sci* 116, 3471-8 (2003)

155. L. Stephens, L. Milne, and P. Hawkins, Moving towards a better understanding of chemotaxis. *Curr Biol* 18, R485-94 (2008)

156. T.M. Brusko, A.L. Putnam, and J.A. Bluestone, Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. *Immunol Rev* 223, 371-90 (2008)

157. S. Sakaguchi, Regulatory T cells: history and perspective. *Methods Mol Biol* 707, 3-17 (2011)

158. S. Sakaguchi, Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. *Annu Rev Immunol* 22, 531-62 (2004)

159. C.L. Bennett, J. Christie, F. Ramsdell, M.E. Brunkow, P.J. Ferguson, L. Whitesell, T.E. Kelly, F.T. Saulsbury, P.F. Chance, and H.D. Ochs, The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* 27, 20-1 (2001)

160. F. Ramsdell, and S.F. Ziegler, Transcription factors in autoimmunity. *Curr Opin Immunol* 15, 718-24 (2003)

161. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25)

Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 155, 1151-64 (1995)

162. M.G. Roncarolo, and M.K. Levings, The role of different subsets of T regulatory cells in controlling autoimmunity. *Curr Opin Immunol* 12, 676-83 (2000)

163. M. Itoh, T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka, and S. Sakaguchi, Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. *J Immunol* 162, 5317-26 (1999)

164. M. Papiernik, M.L. de Moraes, C. Pontoux, F. Vasseur, and C. Penit, Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. *Int Immunol* 10, 371-8 (1998)

165. A.M. Thornton, and E.M. Shevach, Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. *J Immunol* 164, 183-90 (2000)

166. C. Baecher-Allan, J.A. Brown, G.J. Freeman, and D.A. Hafler, CD4+CD25high regulatory cells in human peripheral blood. *J Immunol* 167, 1245-53 (2001)

167. H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A.H. Enk, Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. *J Exp Med* 193, 1285-94 (2001)

168. M.A. Gavin, T.R. Torgerson, E. Houston, P. DeRoos, W.Y. Ho, A. Stray-Pedersen, E.L. Ocheltree, P.D. Greenberg, H.D. Ochs, and A.Y. Rudensky, Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. *Proc Natl Acad Sci U S A* 103, 6659-64 (2006)

169. J. Wang, A. Ioan-Facsinay, E.I. van der Voort, T.W. Huizinga, and R.E. Toes, Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. *Eur J Immunol* 37, 129-38 (2007)

170. S. Sakaguchi, M. Miyara, C.M. Costantino, and D.A. Hafler, FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol* 10, 490-500 (2010)

171. R. Khattri, T. Cox, S.A. Yasayko, and F. Ramsdell, An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol* 4, 337-42 (2003)

172. W. Chen, W. Jin, N. Hardegen, K.J. Lei, L. Li, N. Marinos, G. McGrady, and S.M. Wahl, Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med* 198, 1875-86 (2003)

173. M.A. Curotto de Lafaille, A.C. Lino, N. Kutchukhidze, and J.J. Lafaille, CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. *J Immunol* 173, 7259-68 (2004)

174. K.M. Thorstenson, and A. Khoruts, Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. *J Immunol* 167, 188-95 (2001)

175. M.A. Curotto de Lafaille, N. Kutchukhidze, S. Shen, Y. Ding, H. Yee, and J.J. Lafaille, Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. *Immunity* 29, 114-26 (2008)

176. V.C. Liu, L.Y. Wong, T. Jang, A.H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B.A. Teicher, and C. Lee, Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. *J Immunol* 178, 2883-92 (2007)

177. S.P. Cobbold, R. Castejon, E. Adams, D. Zelenika, L. Graca, S. Humm, and H. Waldmann, Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. *J Immunol* 172, 6003-10 (2004)

178. S.G. Zheng, J. Wang, P. Wang, J.D. Gray, and D.A. Horwitz, IL-2 is essential for TGF-beta to convert naive CD4+. *J Immunol* 178, 2018-2027 (2007)

179. F. Sallusto, and A. Lanzavecchia, Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. *Eur J Immunol* 39, 2076-82 (2009)

180. J.C. Ochando, A.C. Yopp, Y. Yang, A. Garin, Y. Li, P. Boros, J. Llodra, Y. Ding, S.A. Lira, N.R. Krieger, and J.S. Bromberg, Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. *J Immunol* 174, 6993-7005 (2005)

181. L. Graca, S.P. Cobbold, and H. Waldmann, Identification of regulatory T cells in tolerated allografts. *J Exp Med* 195, 1641-1646 (2002)

182. I. Lee, L. Wang, A.D. Wells, M.E. Dorf, E. Ozkaynak, and W.W. Hancock, Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. *J Exp Med* 201, 1037-1044 (2005)

183. J.F. Bach, Regulatory T cells under scrutiny. *Nat Rev Immunol* 3, 189-198 (2003)

184. A.D. Luster, The role of chemokines in linking innate and adaptive immunity. *Curr Opin Immunol* 14, 129-135 (2002)

185. K.J. Wood, and S. Sakaguchi, Regulatory T cells in transplantation tolerance. *Nat Rev Immunol* 3, 199-210 (2003)

186. H.W. Lim, P. Hillsamer, and C.H. Kim, Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. *J Clin Invest* 114, 1640-1649 (2004)

187. G.M. Venturi, R.M. Conway, D.A. Steeber, and T.F. Tedder, CD25+CD4+ regulatory T cell migration requires L-selectin expression: L-selectin transcriptional regulation

balances constitutive receptor turnover. *J Immunol* 178, 291-300 (2007)

188. V. Szanya, J. Ermann, C. Taylor, C. Holness, and C.G. Fathman, The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. *J Immunol* 169, 2461-2465 (2002)

189. J. Ermann, P. Hoffmann, M. Edinger, S. Dutt, F.G. Blankenberg, J.P. Higgins, R.S. Negrin, C.G. Fathman, and S. Strober, Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. *Blood* 105, 2220-2226 (2005)

190. Y. Bai, J. Liu, Y. Wang, S. Honig, L. Qin, P. Boros, and J.S. Bromberg, L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. *J Immunol* 168, 1579-89 (2002)

191. M.A. Schneider, J.G. Meingassner, M. Lipp, H.D. Moore, and A. Rot, CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. *J Exp Med* 204, 735-45 (2007)

192. H. von Boehmer, Mechanisms of suppression by suppressor T cells. *Nat Immunol* 6, 338-44 (2005)

193. Q. Tang, J.Y. Adams, A.J. Tooley, M. Bi, B.T. Fife, P. Serra, P. Santamaria, R.M. Locksley, M.F. Krummel, and J.A. Bluestone, Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. *Nat Immunol* 7, 83-92 (2006)

194. A. Liston, and A.Y. Rudensky, Thymic development and peripheral homeostasis of regulatory T cells. *Curr Opin Immunol* 19, 176-185 (2007)

195. J. Huehn, K. Siegmund, J.C. Lehmann, C. Siewert, U. Haubold, M. Feuerer, G.F. Debes, J. Lauber, O. Frey, G.K. Przybylski, U. Niesner, R.M. de la, C.A. Schmidt, R. Brauer, J. Buer, A. Scheffold, and A. Hamann, Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. *J Exp Med* 199, 303-313 (2004)

196. W.W. Agace, J.M. Higgins, B. Sadasivan, M.B. Brenner, and C.M. Parker, T-lymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta(7), LEEP-CAM and chemokines. *Curr Opin Cell Biol* 12, 563-568 (2000)

197. M.A. Linterman, W. Pierson, S.K. Lee, A. Kallies, S. Kawamoto, T.F. Rayner, M. Srivastava, D.P. Divekar, L. Beaton, J.J. Hogan, S. Fagarasan, A. Liston, K.G. Smith, and C.G. Vinuesa, Foxp3+ follicular regulatory T cells control the germinal center response. *Nat Med* 17, 975-982 (2011)

198. Y. Chung, S. Tanaka, F. Chu, R.I. Nurieva, G.J. Martinez, S. Rawal, Y.H. Wang, H. Lim, J.M. Reynolds, X.H. Zhou, H.M. Fan, Z.M. Liu, S.S. Neelapu, and C. Dong, Follicular regulatory T cells expressing Foxp3 and

Bcl-6 suppress germinal center reactions. *Nat Med* 17, 983-988 (2011)

199. K. Siegmund, M. Feuerer, C. Siewert, S. Ghani, U. Haubold, A. Dankof, V. Krenn, M.P. Schon, A. Scheffold, J.B. Lowe, A. Hamann, U. Syrbe, and J. Huehn, Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. *Blood* 106, 3097-104 (2005)

200. A. Schwarz, A. Maeda, M.K. Wild, K. Kernebeck, N. Gross, Y. Aragane, S. Beissert, D. Vestweber, and T. Schwarz, Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. *J Immunol* 172, 1036-43 (2004)

201. J.C. Dudda, and S.F. Martin, Tissue targeting of T cells by DCs and microenvironments. *Trends Immunol* 25, 417-21 (2004)

202. J.H. Lee, S.G. Kang, and C.H. Kim, FoxP3+ T cells undergo conventional first switch to lymphoid tissue homing receptors in thymus but accelerated second switch to nonlymphoid tissue homing receptors in secondary lymphoid tissues. *J Immunol* 178, 301-11 (2007)

203. B.G. Engelhardt, M. Jagasia, B.N. Savani, N.L. Bratcher, J.P. Greer, A. Jiang, A.A. Kassim, P. Lu, F. Schuening, S.M. Yoder, M.T. Rock, and J.E. Crowe, Jr., Regulatory T cell expression of CLA or alpha(4)beta(7) and skin or gut acute GVHD outcomes. *Bone Marrow Transplant* 46, 436-42 (2010)

204. A. Iellem, L. Colantonio, and D. D'Ambrosio, Skinversus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells. *Eur J Immunol* 33, 1488-96 (2003)

205. K. Hirahara, L. Liu, R.A. Clark, K. Yamanaka, R.C. Fuhlbrigge, and T.S. Kupper, The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. *J Immunol* 177, 4488-94 (2006)

206. D. Valmori, A. Merlo, N.E. Souleimanian, C.S. Hesdorffer, and M. Ayyoub, A peripheral circulating compartment of natural naive CD4 Tregs. *J Clin Invest* 115, 1953-62 (2005)

207. J. Lehmann, J. Huehn, R.M. de la, F. Maszyna, U. Kretschmer, V. Krenn, M. Brunner, A. Scheffold, and A. Hamann, Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as. *Proc Natl Acad Sci U S A* 99, 13031-13036 (2002)

208. L. Zou, B. Barnett, H. Safah, V.F. Larussa, M. Evdemon-Hogan, P. Mottram, S. Wei, O. David, T.J. Curiel, and W. Zou, Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. *Cancer Res* 64, 8451-8455 (2004)

209. M. Feuerer, P. Beckhove, N. Garbi, Y. Mahnke, A. Limmer, M. Hommel, G.J. Hammerling, B. Kyewski, A.

Hamann, V. Umansky, and V. Schirrmacher, Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nat Med* 9, 1151-1157 (2003)

210. I.B. Mazo, M. Honczarenko, H. Leung, L.L. Cavanagh, R. Bonasio, W. Weninger, K. Engelke, L. Xia, R.P. McEver, P.A. Koni, L.E. Silberstein, and U.H. von Andrian, Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. *Immunity* 22, 259-270 (2005)

211. M.K. Slifka, R. Antia, J.K. Whitmire, and R. Ahmed, Humoral immunity due to long-lived plasma cells. *Immunity* 8, 363-372 (1998)

212. T.C. Becker, S.M. Coley, E.J. Wherry, and R. Ahmed, Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. *J Immunol* 174, 1269-1273 (2005)

213. N.E. van Emmerik, L.M. Vaessen, A.H. Balk, E. Bos, F.H. Claas, and W. Weimar, Progressive accumulation of CTL with high avidity for donor antigens during the development of acute cardiac rejection. *Transplantation* 62, 529-36 (1996)

214. N. Zhang, B. Schroppel, G. Lal, C. Jakubzick, X. Mao, D. Chen, N. Yin, R. Jessberger, J.C. Ochando, Y. Ding, and J.S. Bromberg, Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. *Immunity* 30, 458-69 (2009)

215. C.A. Wysocki, Q. Jiang, A. Panoskaltsis-Mortari, P.A. Taylor, K.P. McKinnon, L. Su, B.R. Blazar, and J.S. Serody, Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. *Blood* 106, 3300-3307 (2005)

216. M. Tomura, T. Honda, H. Tanizaki, A. Otsuka, G. Egawa, Y. Tokura, H. Waldmann, S. Hori, J.G. Cyster, T. Watanabe, Y. Miyachi, O. Kanagawa, and K. Kabashima, Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. *J Clin Invest* 120, 883-93 (2010)

217. A. Menning, C. Loddenkemper, A.M. Westendorf, B. Szilagyi, J. Buer, C. Siewert, A. Hamann, and J. Huehn, Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation. *Eur J Immunol* 40, 2539-48 (2010)

**Key Words:** Homing receptors, T Cells, T lymphocytes, Homing, Migration, Review

**Send correspondence to:** Federica M. Marelli-Berg, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK, Tel: 44-0-20-7882 3443, Fax: 44-0-20-7882 6076, E-mail: f.marelli-berg@qmul.ac.uk